Ejaculation did not increase the risk of pharyngealgonorrhea.
2
To our knowledge, there have been no longitudinal studies in a prospective MSM cohort to estimate pharyngealgonorrhea incidence or predictors of infection.
3
We examined the prevalence, incidence, and sociodemographic and behavioral predictors of pharyngealgonorrhea in a cohort of sexually active, human immunodeficiency virus-negative MSM.
4
Background: The Centers for Disease Control and Prevention guidelines for pharyngealgonorrhea treatment recommend dual therapy with intramuscular ceftriaxone and either azithromycin or doxycycline.
5
Conclusions: In this retrospective study, dual therapy with an oral third-generation cephalosporin and azithromycin was comparable to ceftriaxone-based regimens in the treatment of pharyngealgonorrhea.